Network Insights Methodology Get Access

AstraZeneca

ORG Health Care / Pharmaceuticals Momentum 8.8ML Momentum Score (0-100). Weighted composite of 9 features: mention velocity, article breadth, relationship density, deal context, recency, market cap, enrichment completeness, mention concentration, entity type. NORMALPSI regime classification. QUIET (<0.3): baseline activity. NORMAL (0.3-0.5): typical deal flow. ELEVATED (0.5-0.7): above-average signals. HIGH (0.7-0.85): significant activity. EXTREME (>0.85): exceptional signal concentration. Primary: Spectral Shift

$81B market cap (London-listed), AstraZeneca manufactures oncology, cardiovascular, and respiratory pharmaceuticals. FDA approved baxdrostat in May 2026 as first-in-class aldosterone synthase inhibitor for resistant hypertension, expanding cardiovascular portfolio.

Recent FDA approval of baxdrostat for hypertension treatment; active in oncology and cardiovascular therapeutic areas.
-0.46
PSI ScorePlocamium Signal Index - composite z-score from 5 orthogonal signals: news frequency, targeted sentiment, graph centrality, regulatory filings, and clinical trial activity.
8.8
MomentumML Momentum Score (0-100). Weighted composite of 9 features including mention velocity, article breadth, deal context, and relationship density. Retrained weekly.
1%
ConfidenceSignal confidence - percentage of PSI sub-signals with sufficient data (30+ observations). Higher confidence means the PSI score is based on more complete data.
11
ConnectionsDegree centrality - number of unique entities this entity co-occurs with in news signals and articles. Higher = more connected in the intelligence network.
Connected Entities
FDA European Union China Merck Supreme Court Eli Lilly Pfizer Novo Nordisk Sanofi Novartis United Kingdom
Watch This Entity
PSI Intelligence
30-Day Trend
2026-04-25 2026-05-25 11 0 Degree Mentions
Signal Decomposition
Attention Cascade
0.236
Narrative Drift
0.000
Spectral Shift
624.046
Sentiment-Momentum Divergence
0.000
Source Concentration
0.672
Peer Comparison
Not yet ranked. Sector-relative scoring requires at least four entities in the same BICS sector with PSI history; this entity does not yet meet the threshold or sits in a sector with insufficient peers.
Network Analysis
11 Degree Centrality
Ego Network (top connections)
FDA (weight 18.0)European Union (weight 8.0)China (weight 4.0)Merck (weight 3.0)Supreme Court (weight 3.0)Eli Lilly (weight 3.0)Pfizer (weight 3.0)Novo Nordisk (weight 3.0) FDAEuropean UnionChinaMerckSupreme CourtEli LillyPfizerNovo Nordisk AstraZeneca (degree 11) AstraZeneca
Centrality History
2026-04-25 2026-05-25 11 0 Degree Mentions
EntityWeight StatusFirst Seen
FDA 18 NEW
European Union 8 NEW
China 4 NEW
Merck 3 NEW
Supreme Court 3 NEW
Eli Lilly 3 NEW
Pfizer 3 NEW
Novo Nordisk 3 NEW
Sanofi 2 NEW
Novartis 2 NEW
United Kingdom 2 NEW
Article Coverage (0)
DateLaneTitle
No Plocamium-authored coverage yet. This entity surfaces in upstream signals (news, filings, trials) but has not yet been a primary subject of a published article. Watch this entity to be alerted when one is published.

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Data as of 2026-05-25 ← Intelligence Network